Tivozanib (Fotivda) is a targeted therapeutic drug for relapsed or refractory advanced renal cell carcinoma. The standardized acquisition and safe use of this drug are crucial to the therapeutic effect for patients.

How to Purchase Tivozanib (Fotivda)

Overseas Purchase

Patients may choose to consult and purchase Tivozanib at hospital pharmacies or official pharmacies in countries or regions where the drug has been launched.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase through Medical Service Institutions

Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions can usually provide legal import channels and offer professional consultation and guidance.

Precautions for Purchase and Use of Tivozanib (Fotivda)

Strictly Follow Doctor’s Advice for Medication

The standard dosage of Tivozanib is 1.34 mg taken orally once daily, with or without food. Administer for 21 consecutive days followed by a 7-day drug-free period (a 28-day cycle).

Patients must strictly complete each treatment cycle as prescribed by the doctor until disease progression or unacceptable toxicity occurs.

Medication Warnings for Special Populations

According to the drug label, the use of Tivozanib in pregnant women may cause fetal harm.

Lactating women should discontinue breastfeeding during treatment and for one month after the last dose.

For patients with moderate hepatic impairment, the dose should be adjusted to 0.89 mg taken orally once daily.

Patients with severe hepatic impairment should avoid using this drug.

Special Management Before and After Surgery

Discontinue Tivozanib at least 24 days before elective surgery.

Do not administer the drug for at least 2 weeks after major surgery and until the wound is fully healed.

Patients must communicate with their doctor in advance about the medication adjustment plan before scheduling surgery.

Methods to Identify the Authenticity of Tivozanib (Fotivda)

Verification of Appearance Characteristics

1.34 mg capsules: Bright yellow opaque cap with "TIVZ" printed in dark blue ink; bright yellow opaque body with "SD" printed in dark blue ink.

0.89 mg capsules: Dark blue opaque cap with "TIVZ" printed in yellow ink; bright yellow opaque body with "LD" printed in dark blue ink.

Verification of Packaging Information

The packaging of genuine products should contain complete drug information, including the National Drug Code (NDC), batch number, and expiration date.

Patients should carefully check the integrity of the packaging and the clarity of the information.

Observation of Drug Properties

Authentic capsules should be intact, without leakage, discoloration, or abnormal odor.

It is particularly important to note that 0.89 mg capsules contain tartrazine, which may cause allergic reactions in patients allergic to aspirin.